Denali Therapeutics (DNLI) Other Non-Current Assets: 2017-2025
Historic Other Non-Current Assets for Denali Therapeutics (DNLI) over the last 8 years, with Sep 2025 value amounting to $25.1 million.
- Denali Therapeutics' Other Non-Current Assets fell 5.21% to $25.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.1 million, marking a year-over-year decrease of 5.21%. This contributed to the annual value of $24.7 million for FY2024, which is 36.37% up from last year.
- According to the latest figures from Q3 2025, Denali Therapeutics' Other Non-Current Assets is $25.1 million, which was up 9.30% from $23.0 million recorded in Q2 2025.
- Over the past 5 years, Denali Therapeutics' Other Non-Current Assets peaked at $50.6 million during Q2 2024, and registered a low of $3.6 million during Q2 2021.
- Its 3-year average for Other Non-Current Assets is $25.4 million, with a median of $24.7 million in 2024.
- As far as peak fluctuations go, Denali Therapeutics' Other Non-Current Assets soared by 382.17% in 2021, and later plummeted by 54.58% in 2025.
- Quarterly analysis of 5 years shows Denali Therapeutics' Other Non-Current Assets stood at $11.9 million in 2021, then grew by 12.87% to $13.4 million in 2022, then soared by 35.41% to $18.1 million in 2023, then surged by 36.37% to $24.7 million in 2024, then decreased by 5.21% to $25.1 million in 2025.
- Its Other Non-Current Assets was $25.1 million in Q3 2025, compared to $23.0 million in Q2 2025 and $26.9 million in Q1 2025.